U.S. Chemicals Stock News

Recent performance snapshot for Plug Power Plug Power (PLUG) has caught investor attention after a sharp share price move, with the stock up about 29% over the past month and roughly 50% over the past 3 months. This recent rebound follows a challenging multi year stretch, with the company showing a 67% negative total return over 3 years and an 87% negative total return over 5 years. See our latest analysis for Plug Power. Despite a small pullback in the last week, Plug Power’s share price has...

If you are wondering whether Haemonetics at around US$59.26 is a bargain or just fairly priced right now, this article walks through what the numbers say about its value. The stock has seen mixed returns, with a 1.1% decline over the last 7 days, a 4.3% gain over 30 days, and year to date and 1 year returns of 25.9% and 7.2% declines. These movements may be prompting new questions about risk and opportunity. Recent news coverage has focused on Haemonetics as part of broader discussions...

In the first quarter of 2026, Iridium Communications Inc. reported revenue of US$219.06 million versus US$214.88 million a year earlier, while net income fell to US$21.59 million from US$30.41 million and diluted EPS from continuing operations eased to US$0.20 from US$0.27. Iridium also reiterated its 2026 outlook for total service revenue to be flat to 2%, signaling a cautious near-term growth profile despite higher quarterly sales. With Iridium reaffirming expectations for flat to slightly...

What Landstar’s latest quarter tells you Landstar System (LSTR) just released first quarter results, with sales of US$1,149.56 million and net income of US$39.44 million, and reported basic EPS from continuing operations of US$1.16. Management also highlighted heavy haul revenue, lower insurance and claims costs, AI-related initiatives, and a focus on U.S. Mexico cross border freight and carrier vetting, giving investors more context than the headline numbers alone. See our latest analysis...

Donaldson Company stock overview Donaldson Company (DCI) has drawn investor attention after a mixed stretch for the share price, with a negative move over the past 3 months contrasting with a positive total return over the past year. At a recent close of $86.22, the filtration specialist and its segments across Mobile Solutions, Industrial Solutions, and Life Sciences are set against a backdrop of single digit annual revenue growth and double digit annual net income growth. See our latest...

Carrier Global (CARR) is back in focus after Q1 2026 results topped expectations, total orders rose 11%, and data center demand was strong enough to fully cover the company’s targeted 2026 sales. See our latest analysis for Carrier Global. The Q1 beat and reaffirmed 2026 guidance have been met with strong buying interest, with a 21.38% 1 month share price return and 26.35% year to date, even though the 1 year total shareholder return is down 4.42%, so momentum is clearly building off a longer...

How H.B. Fuller Stock Has Been Trading Recently H.B. Fuller (FUL) has seen relatively muted share performance lately, with the stock around $59.95 and negative returns over the past week, month, and past 3 months, despite a positive 1 year total return. For context, the company carries a market value of about $3.27b and generates annual revenue of roughly $3.46b with net income of about $159.76m. This reflects its role as an established adhesives and specialty chemicals supplier. See our...

In the first quarter of 2026, OneMain Holdings reported net income of US$226 million, up from US$213 million a year earlier, and affirmed a quarterly dividend of US$1.05 per share payable on May 15, 2026. Beyond headline earnings, growth in auto finance and credit card receivables, supported by cost-saving AI tools and disciplined underwriting, underscored management’s push to broaden revenue sources while maintaining credit stability. Next, we’ll examine how this receivables growth in newer...

In the past quarter, LSB Industries, Inc. reported first‑quarter 2026 sales of US$169.49 million, up from US$143.43 million a year earlier, and moved from a net loss to net income of US$19.69 million, with basic and diluted earnings per share from continuing operations at US$0.27. Beyond the headline turnaround, the results were supported by tight nitrogen fertilizer markets, improved production performance, and progress on LSB’s El Dorado carbon capture and sequestration project, alongside...

If you are wondering whether DaVita at around US$151.65 is still priced reasonably or already baking in a lot of optimism, the next sections will help you frame that question clearly. The stock's recent performance has been mixed in the short term, with a 0.1% decline over 7 days, a 4.2% gain over 30 days, and longer term returns of 32.4% year to date, 7.5% over 1 year, 71.4% over 3 years, and 19.6% over 5 years. Recent coverage has focused on DaVita's role in the US healthcare system and...

Recent share performance and business snapshot Grand Canyon Education (LOPE) has seen its share price under pressure recently, with a 3.3% decline over the past day, a 4.6% drop over the past month, and a 6.7% fall in the past 3 months. Over a longer horizon, the stock shows a 1.2% decline year to date and a 12.3% total return decline over the past year, set against a 45.8% total return gain across 3 years and 72.9% over 5 years. See our latest analysis for Grand Canyon Education. The recent...

Kodiak Sciences (KOD) is back in focus after sharing new KSI-101 clinical data in Asian MESI patients at the AUS and ARVO meetings, reinforcing interest in its expanding retinal disease pipeline. See our latest analysis for Kodiak Sciences. The clinical updates around KSI-101 arrive after a sharp re-rating in Kodiak Sciences, with the share price at US$43.96 and a 90-day share price return of 82.33%, contributing to a very large 1-year total shareholder return, while the 5-year total...

Pegasystems (PEGA) is back in focus after first quarter earnings showed revenue of US$429.97 million and net income of US$32.76 million, alongside growing attention on its AI native Blueprint platform and customer engagement trends. See our latest analysis for Pegasystems. The first quarter update and growing attention on the Blueprint platform come against a tougher trading backdrop, with a 30 day share price return showing a 15.06% decline and year to date share price return showing a...

HubSpot (HUBS) has been back in focus after a sector wide lift in software as a service names, as well as growing attention on its AI products, customer growth, and upcoming earnings report. See our latest analysis for HubSpot. The recent 8.2% one day share price gain sits against a weaker backdrop, with a year to date share price return of 37.24% decline and a 1 year total shareholder return of 62.27% decline. This suggests short term momentum has picked up while longer term performance...

HCA Healthcare (NYSE:HCA) is opening a new full-service hospital in Gainesville, the first new facility of its kind in the area in more than 50 years. The company is planning a substantial expansion at Kendall Hospital in Miami-Dade, aimed at increasing capacity and service reach in South Florida. Cynthia Cifuentes-Finkel has been appointed senior vice president of marketing and corporate affairs, with responsibility for brand leadership and stakeholder engagement. For investors watching...

In late April 2026, Align Technology reported first-quarter sales of US$1,040.09 million and net income of US$112.77 million, beating analyst expectations while reaffirming its full-year 2026 guidance and announcing an additional US$200 million share repurchase under its existing US$1 billion program. At the same time, Align used the AAO 2026 conference to showcase advances across its digital orthodontic platform, including 3D printed attachment systems, enhanced palatal expanders, and...

Regulatory approval shifts focus to CRISPR Therapeutics stock CRISPR Therapeutics (CRSP) has moved into the spotlight after securing regulatory approval for its first gene editing therapy, Casgevy, for blood disorders, along with progress in its CAR T pipeline. See our latest analysis for CRISPR Therapeutics. At a share price of US$51.63, CRISPR Therapeutics has seen short term momentum pick up, with a 7 day share price return of 5.83%, while the 1 year total shareholder return of 34.98%...

If you are wondering whether A10 Networks at around US$26.85 is priced attractively or already baking in a lot of optimism, this breakdown is designed to help you frame that question clearly. The stock has seen a 2.6% decline over the last 7 days, alongside returns of 11.9% over 30 days, 54.8% year to date, 65.9% over 1 year, 104.3% over 3 years and 214.4% over 5 years. These movements can change how the market views both its potential and its risks. Recent coverage has focused on A10...

Chime Financial (NasdaqGS:CHYM) has partnered with Junior Achievement USA to roll out AI powered financial literacy programs for students. The partnership includes a redesign of the JA Finance Park program to introduce interactive, experiential money management and career readiness modules. The initiative launches during Financial Literacy Month and focuses on preparing young people for real world financial decisions. For investors tracking Chime Financial, the partnership arrives as the...

Rezolve AI's SQD token has been listed on Revolut, expanding access to more than 70 million users worldwide. The listing brings SQD onto a large mainstream fintech platform, beyond crypto focused exchanges. This move is positioned as a step toward mass market adoption of Rezolve AI's decentralized AI commerce infrastructure. Rezolve AI, listed as NasdaqGM:RZLV, is building a decentralized AI commerce infrastructure designed to connect agentic AI systems with real world transactional data...

Erasca (NasdaqGS:ERAS) disclosed a patient death in its Phase 1 ERAS-0015 trial, triggering heightened safety and regulatory scrutiny. Revolution Medicines filed a patent infringement lawsuit against Erasca, also challenging the way ERAS-0015 has been compared to its own programs. These events follow a recent preliminary positive data update for ERAS-0015 and introduce fresh uncertainty around the asset and broader pipeline. Erasca comes into this twin shock with a share price of $10.03 and...

If you are trying to figure out whether Madrigal Pharmaceuticals is priced attractively today, the starting point is understanding what the current share price really reflects. The stock most recently closed at US$513.72, with returns of 0.3% over 7 days, a 6.1% decline over 30 days, a 13.5% decline year to date, a 62.8% return over 1 year, a 67.7% return over 3 years, and a very large 5 year gain of 293.9%. These mixed short term and longer term moves have kept Madrigal on the radar of...

Solaris Energy Infrastructure (SEI) is back in focus after first quarter 2026 results showed higher sales, revenue, and net income versus a year earlier, along with raised earnings guidance and expanded long term power contracts. See our latest analysis for Solaris Energy Infrastructure. SEI shares have cooled slightly after recent highs, with a 1 day share price return of 2.04% and a relatively flat 7 day move. However, the 30 day share price return of 29.62% and year to date gain of 43.91%...

Why AnaptysBio is on investors’ radar AnaptysBio (ANAB) has attracted attention after a recent share price move, with the stock showing double digit returns over the past week, month and past 3 months. This performance is prompting some investors to reassess its profile. See our latest analysis for AnaptysBio. Beyond the recent surge, the momentum in AnaptysBio’s share price return has been building for some time, and the very large 1 year total shareholder return suggests investors have been...